Sanofi, Regeneron Report Alirocumab Met Primary Endpoint in Phase III Odyssey Mono

Sanofi and Regeneron are satisfied with a Phase III trial of alirocumab that met its primary endpoint of reducing levels of the “bad” LDL cholesterol.
Street Insider